Your Peptide Partner For Your Contract Manufacturing and Services

UCB-Bioproducts

UCB-Bioproducts is a Belgian based, internationalContract Services Company, focusing on custompeptide and peptidomimetics (for pharmaceuticaluse) process development, regulatory services andmanufacturing services along with strong supportto customers’ clinical trials.

UCB-Bioproducts mission is to create value by supporting pharmaceutical players to bring innovative drugs to the market to improve the livesof people.

With double digit revenue growth and around 300employees worldwide : in Belgium (Brussels), in theUSA (Cambridge-Boston, MA and North Augusta,SC) and in Japan (Tokyo), UCB-Bioproducts is arecognised leader in the field of industrial pharma-ceutical peptides and is currently the supplier of themajority of approved commercial peptides as NewChemical Entities.

UCB-Bioproducts growth is expected to continue atan accelerated pace following current advances inthe peptides based therapeutic field and given itsstrong partnership with well established partners.

Business StrategyUCB-Bioproducts capitalizes on over 25 years ofexpertise in peptides and is committed to supportpeptide projects using its combination of uniquepeptide know-how, constantly evolving techno-logy/equipment and a vast experience in peptidemanufacturing and services related to processdevelopment and clinical trials.

UCB-Bioproducts creates value by meeting customers’ immediate requirements thanks to flexible and fast access to peptides and resourcesfrom sites in Belgium and United States and byanticipating long-term expectations and milestones(both on product availability and regulatoryaspects). This enables UCB-Bioproducts to offerICH/cGMP compliant development activities, commercial manufacturing capacities and capabilities supporting regulatory aspects whichare customized to the needs of each customer andeach stage of a customers’ clinical trial in an openpartnership spirit.

UCB-Bioproducts provides a complete range ofsolutions to its customers through a large-scalecapacity in its FDA-approved facilities and its strongregulatory expertise for supporting peptide active

pharmaceutical ingredient (API) registration. Thanksto its internal research and its close ties toUniversities, UCB-Bioproducts also develops andoffers innovative technologies. From research toproduction, from preliminary clinical trials to product registration, a comprehensive set of services and manufacturing capacities are available.

UCB-Bioproducts has recently entered into the longpeptide synthesis field (up to 150 amino-acids) byacquiring Dictagene’s established IntellectualProperty, technology, skills, know-how and equipment. UCB-Bioproducts strongly believes thisis an important milestone which will enable thispromising segment to develop further.

By extending its product and services offering tolong peptides and by continued investment in cGMPproduction capacities and capabilities (R&D,Regulatory Services, Process Development, ...) UCB-Bioproducts continues to position itself as aleading supplier of peptide API’s to the fast growingand demanding Biopharmaceutical industry, fromearly clinical trials requirements to drug commercialization.

APRIL 2005

Your Peptide Partner For Your Contract Manufacturing and Services

UCB-Bioproducts

• Open (non “black box”) partnership with customers on a large number of projects in various stages of clinical development from preclinical to commercial.

• Partnership supporting successful commercia-lization of 4 new chemical entities (NCE) drugs.

• Continued capacity and capability investments over the years; culminating in 2005 and with solid projects for years beyond.

• Entry in the long peptide synthesis field (up to 150 amino-acids) by acquiring established and demonstrated I.P., technology, skills, know-how and equipment in order to sustain the broad offering strategy.

• Optimization of the North Augusta facilities to focus on specific projects in anticipation of a second large scale manufacturing site currently being contemplated.

• Opening of a new commercial USA Representative Office in Cambridge-Boston, MA (May 2005) with senior managers relocating in order to better support growth, improve proximity to customers, and to prepare for future plans.

• Long peptides synthesis (up to 150 amino-acids) services should be available to customers by end of Q2 2005.

Strategy - Facts

UCB-Bioproducts

EUROPEChemin du ForiestB-1420 Braine-l'Alleud BelgiumTel. +32.2.386.2111Fax. +32.2.386.2990

USA Cambridge Innovation CenterOne Broadway, 14th floorCambridge, MA 02142Tel. +1.617.682.3641Fax. +1.617.225.4492

JAPANOchanomizu Kyoun Building 2-2 Kanda-SurugadaiChiyoda-ku, Tokyo 101-0062Tel. +81.3.5283.1714Fax. +81.3.5283.1948

E-mail: peptide.partner@ucb-group.comWeb: www.ucb-bioproducts.com

Key Data

Founded 1981Employees (March 2005) 3112004 Revenue Growth vs 2003 > 15 %Planned 2005 Revenue Growth vs 2004 > 15 %Partnerships with Approved commercial peptide drugs (ex Generics) 4Long peptide (up to 150 amino acids) acquisition closure April 2005New USA office opens, Cambridge-Boston, MA May 2005Long peptides services available to customers July 2005Significant continued capacity increase via investments next milestone August 2005

Management TeamAndré Jordens PresidentAlain Scarso Vice President

Vincent Bille Director, Commercial OperationsCleo Ricci Director, Business Unit